GLP-1 Approval Timeline: 2021 Through 2030
A complete roadmap of approved medications, drugs in late-stage trials, and estimated approval windows — updated with the latest trial data.
While the next generation completes trials, FDA-approved GLP-1 medications achieving 15–22% weight loss are accessible through telehealth in most states.
From Approval to Anticipated Availability
Each stage represents a meaningful development milestone. Colors indicate regulatory status at time of writing.
Wegovy (semaglutide 2.4mg) — Novo Nordisk
First high-dose GLP-1 approved specifically for chronic weight management. ~15% average weight loss at 68 weeks. Available through telehealth in most states.
Zepbound (tirzepatide) — Eli Lilly
Dual GLP-1 + GIP agonist. ~20–22% average weight loss at 72 weeks — highest efficacy of any currently approved obesity medication. Available through telehealth.
CagriSema — Novo Nordisk
REDEFINE Phase 3 program nearing completion. Combined semaglutide + cagrilintide showed 22.7% weight loss. NDA submission and FDA review to follow approval possible late 2026.
Orforglipron — Eli Lilly
ATTAIN Phase 3 program results expected late 2025–2026. First true oral GLP-1 pill — no food restrictions. Could be the next drug approved after CagriSema.
Retatrutide — Eli Lilly
TRIUMPH Phase 3 results expected 2025–2026. Triple agonist with highest Phase 2 weight loss of any drug in history (~24%). NDA submission and 12-month FDA review to follow.
MariTide — Amgen
MARITIME Phase 3 underway. Monthly dosing with ~20% Phase 2 weight loss. Bispecific antibody — a fundamentally different drug type from all existing GLP-1 therapies.
Amycretin — Novo Nordisk
Currently in Phase 2. Oral GLP-1 + amylin single molecule with a striking Phase 1 signal. Earliest realistic approval window 2029–2030 — if Phase 2 and Phase 3 succeed.
All Drugs — Status at a Glance
| Drug | Developer | Form | Avg Weight Loss | Phase | Est. Approval |
|---|---|---|---|---|---|
| Wegovy | Novo Nordisk | Weekly inj. | ~15% | Approved | Available now |
| Zepbound | Eli Lilly | Weekly inj. | ~20–22% | Approved | Available now |
| CagriSema | Novo Nordisk | Weekly inj. | 22.7% | Phase 3 | 2026–2027 |
| Orforglipron | Eli Lilly | Daily pill | ~15% | Phase 3 | 2026–2027 |
| Retatrutide | Eli Lilly | Weekly inj. | ~24% | Phase 3 | 2027–2028 |
| MariTide | Amgen | Monthly inj. | ~20% | Phase 3 | 2027–2028 |
| Amycretin | Novo Nordisk | Daily pill | ~13% (12wk) | Phase 2 | 2029–2030 |
Important: Timelines are estimates, not guarantees
Drug development timelines shift frequently. A single unexpected safety signal in Phase 3 can delay or stop a program entirely. Multiple drugs with strong Phase 2 results have failed to reach approval. The timelines above reflect the most optimistic realistic scenarios based on publicly available trial data as of May 2026. Always verify with current sources before making treatment decisions.
FDA-approved options with 15–22% weight loss are available today. You can always reassess when new drugs reach approval.